Same Indication

Pembrolizumab vs Sars-Cov-2 Virus Spike Protein

Pembrolizumab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Sars-Cov-2 Virus Spike Protein.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab β€” 26 days.

Chemical Properties

Type: Pembrolizumab β€” Antibody; Sars-Cov-2 Virus Spike Protein β€” Vaccine component.